{
    "clinical_study": {
        "@rank": "13417", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects in the control arm will not receive an intervention."
            }, 
            {
                "arm_group_label": "CardioLife", 
                "arm_group_type": "Experimental", 
                "description": "The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of the metabolic and physiological characteristics of patients with diagnosed\n      Cardiovascular Disease following administration of the Cardiovascular vitamin, CardioLife."
        }, 
        "brief_title": "Study of the Cardiovascular Vitamin, CardioLife", 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 - 90 years old and ability to understand the planned study.\n\n          -  Patients with Cardiovascular Disease\n\n          -  Able to comply with all study-related visits\n\n          -  Able to give Informed Consent\n\n          -  Negative for HcG with a serum pregnancy test\n\n          -  If the patient has diabetes mellitus it must be controlled (HbA1c < 9.0%)\n\n          -  Life expectancy of 1 year or more in the opinion of the investigator.\n\n          -  Hematocrit \u2265 28.0%, White Blood Cell count \u2264 14,000, Platelet count \u2265 50,000, Serum\n             bilirubin, ALT, AST x 2.5 time the upper level of normal.\n\n          -  Controlled blood pressure (systolic blood pressure \u2264160 and a diastolic blood\n             pressure of \u2264100 mmHG) and established anti-hypertensive therapy as necessary prior\n             to entry into the study\n\n          -  Patient must be on at least three of the listed medications for at least 30 days with\n             no new medications to treat the disease introduced in the last month. Medications\n             are: Anti-Platelet Therapy, Beta-Blockers, ACE/ARB, Calcium Blocker, Nitrates, After\n             Load Reducing Agents, Lipid Lowering Agents, and/or Diuretics.   Cardiac medications\n             must be at stable doses with no dose change within the last 30 days.\n\n        Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia are\n        adequately controlled in the opinion of the investigator)\n\n          -  Fertile patients (male and female) must agree to use an appropriate form of\n             contraception while participating in the study.\n\n        Exclusion Criteria:\n\n          -  Female who is pregnant or nursing, or of child bearing potential and is not using a\n             reliable birth control method, or who intend to become pregnant during the tenure of\n             this study.\n\n          -  End stage renal disease (Creatinine \u2264 3.0 mg / dl) and/or dialysis\n\n          -  Acute Myocardial Infarction 90 days prior to randomization.\n\n          -  Inability or unwillingness to comply with the treatment protocol, follow-up, research\n             tests, or give consent.\n\n          -  Life expectancy <1 year due to concomitant illnesses\n\n          -  Known cancer or malignancy within the last 5 years\n\n          -  Prior admission for substance abuse\n\n          -  Uncontrolled lipid levels as determined by the Investigator\n\n          -  Untreated Hypothyroidism\n\n          -  Known Congenital Heart Defects\n\n          -  History of Ischemic and Non-Ischemic Cardiomyopathy or Heart Failure\n\n          -  Body Mass Index (BMI) of 45 kg/m2 or greater\n\n          -  Medication use of steroids 30 days prior to enrollment\n\n          -  Current use of any Nutraceutical that contains ingredients known to affect blood\n             pressure, or any active ingredients that are found in CardioLifeTM\n\n          -  Patient receiving experimental medication or participating in another clinical study\n             within 30 days of signing the informed consent\n\n          -  In the opinion of the investigator or the sponsor, the patient is unsuitable for\n             cellular therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088307", 
            "org_study_id": "CARDIOLIFE--001"
        }, 
        "intervention": {
            "arm_group_label": "CardioLife", 
            "intervention_name": "CardioLife", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Vitamins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cardiovascular supplement", 
            "cardiovascular disease", 
            "coronary artery disease"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "Michelle.Esplin@hsc.utah.edu", 
                "last_name": "Michelle Esplin, BS", 
                "phone": "801-585-5243"
            }, 
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84132"
                }, 
                "name": "University of Utah Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Anwar Tandar, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Metabolic and Physiological Profiles of Patients Diagnosed With Cardiovascular Disease (CVD) Following Administration of the Novel Cardiovascular Vitamin, CardioLife", 
        "overall_contact": {
            "email": "Michelle.Esplin@hsc.utah.edu", 
            "last_name": "Michelle Esplin, BS", 
            "phone": "801-585-5243"
        }, 
        "overall_official": {
            "affiliation": "University of Utah", 
            "last_name": "Anwar Tandar, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in blood pressure", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088307"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Utah", 
            "investigator_full_name": "Anwar Tandar", 
            "investigator_title": "Assistant Professor (Clinical), Division of Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in serum lipid levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "Change plasma levels of endothelial progenitor cells (EPC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Months"
            }, 
            {
                "measure": "Change in cholesterol levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in homocysteine levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in erythrocyte sedimentation rate (ESR) levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in hs-C-reactive protein (CRP) levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}